Breaking News Instant updates and real-time market news.

MDRX

Allscripts

$13.04

-0.01 (-0.08%)

16:51
10/05/16
10/05
16:51
10/05/16
16:51

Allscripts initiated with a Buy at UBS

Target $17.

MDRX Allscripts
$13.04

-0.01 (-0.08%)

08/23/16
08/23/16
UPGRADE
Target $17

Outperform
Allscripts upgraded to Outperform at Leerink
As previously reported, Leerink analyst David Larsen upgraded Allscripts to Outperform from Market Perform saying he believes that the company's core fundamentals are improving "significantly." The analyst expects adjusted EPS to grow by over 20% year over year in 2016 and 2017, and believes that Allscripts is becoming a more attractive acquisition candidate. Larsen also raised his price target on the shares to $17 from $16.
08/23/16
08/23/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he now feels more confident in the company's growth and profitability outlook and its competitive position following three quarters of consistent execution. 2. BHP Billiton (BHP) upgraded to Buy from Hold at Jefferies with analyst Christopher LaFemina saying he believes fundamentals have "clearly improved," citing supply that has declined in most cases and demand that has stabilized. 3. SoftBank (SFTBF) upgraded to Overweight from Neutral at JPMorgan with analyst Jun Tanabe citing improved earnings at Sprint (S), the growth in value of its stake in Alibaba (BABA), and the stability of cash flow in its domestic mobile business. 4. Allscripts (MDRX) upgraded to Outperform from Market Perform at Leerink with analyst David Larsen saying he believes that the company's core fundamentals are improving "significantly." 5. Westlake Chemical (WLK) upgraded to Outperform from Sector Perform at RBC Capital with analyst Arun Viswanathan saying that the company's merger with Axiall (AXLL) "creates a new way to play chlor-alkali," as well as synergies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/16
RHCO
08/29/16
NO CHANGE
RHCO
Allscripts fundamentals improving, says SunTrust
SunTrust analyst Sandy Draper says that Allscripts' fundamentals appear to be improving, as its organic bookings growth in 2H16 came in at about 15%, up from approximately 8.5% in 2H15. However, the analyst says that, "evidence of stabilized client retention, growth in recurring revenue and better backlog pull-through is needed to catalyze upside in the stock." He keeps a $15 price target and Buy rating on the shares.
09/08/16
COWN
09/08/16
DOWNGRADE
Target $14
COWN
Market Perform
Allscripts downgraded to Market Perform from Outperform at Cowen
Cowen analyst Charles Rhyee downgraded Allscripts to Market Perform saying valuation reflects moderating long-term growth expectations driven by a more mature core EHR market and lack of new revenue growth opportunities. The analyst said Allscripts reliance on services in a period of continued decline in system sales also continues to pressure top-line growth and lowered his price target on shares to $14 from $17.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.